

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Chemical product name : Pembrolizumab Liquid Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.  
Menuuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS classification of chemical product**

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Immune system)

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapours.  
P280 Wear protective gloves/ protective clothing/ eye protec-

## Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

tion/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Sucrose	57-50-1	$\geq 1 - < 10$	
Pembrolizumab	1374853-91-4	$\geq 1 - < 10$	-

**4. FIRST AID MEASURES**

- |                                                             |                                                                                                                                                                                                                         |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| General advice                                              | : In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.                                                                |
| If inhaled                                                  | : If inhaled, remove to fresh air.<br>Get medical attention.                                                                                                                                                            |
| In case of skin contact                                     | : In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact                                      | : Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.                                                                                                                  |
| If swallowed                                                | : If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.                                                                                                                 |
| Most important symptoms and effects, both acute and delayed | : May damage the unborn child.<br>May cause damage to organs through prolonged or repeated exposure if swallowed.                                                                                                       |
| Protection of first-aiders                                  | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).                                           |
| Notes to physician                                          | : Treat symptomatically and supportively.                                                                                                                                                                               |

**Pembrolizumab Liquid Formulation**

Version 8.1	Revision Date: 2025/04/14	SDS Number: 49570-00028	Date of last issue: 2024/09/28 Date of first issue: 2015/01/23
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

**5. FIREFIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

**Pembrolizumab Liquid Formulation**

Version 8.1	Revision Date: 2025/04/14	SDS Number: 49570-00028	Date of last issue: 2024/09/28 Date of first issue: 2015/01/23
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE****Handling**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.

**Storage**

- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m <sup>3</sup>	ACGIH
Pembrolizumab	1374853-91-	TWA	450 µg/m <sup>3</sup> (OEB	Internal

## Pembrolizumab Liquid Formulation

Version 8.1	Revision Date: 2025/04/14	SDS Number: 49570-00028	Date of last issue: 2024/09/28 Date of first issue: 2015/01/23
----------------	------------------------------	----------------------------	-------------------------------------------------------------------

	4		2)	
--	---	--	----	--

**Engineering measures** : Minimize workplace exposure concentrations.  
If sufficient ventilation is unavailable, use with local exhaust ventilation.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection** : Wear the following personal protective equipment:  
Safety glasses

**Skin and body protection** : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical state** : suspension

**Colour** : Colorless to pale yellow

**Odour** : No data available

**Odour Threshold** : No data available

**Melting point/freezing point** : No data available

**Boiling point, initial boiling point and boiling range** : No data available

**Flammability (solid, gas)** : Not applicable

**Flammability (liquids)** : No data available

**Lower explosion limit and upper explosion limit / flammability limit**  
**Upper explosion limit / Up-** : No data available

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

per flammability limit

Lower explosion limit /  
Lower flammability limit : No data available

Flash point : No data available

Decomposition temperature : No data available

pH : 5.5

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-  
octanol/water : No data available

Vapour pressure : No data available

Density and / or relative density

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-  
tions : Can react with strong oxidizing agents.

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Sucrose:**

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Sucrose:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

May damage the unborn child.

**Components:****Pembrolizumab:**

Reproductive toxicity - As- : May damage the unborn child., Based on data from similar

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

essment

materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

**Components:****Pembrolizumab:**

Target Organs	: Immune system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Pembrolizumab:**

Species	: Monkey
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Pembrolizumab:**

Inhalation	: Target Organs: Immune system Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis Remarks: Damage to fetus possible
------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

**12. ECOLOGICAL INFORMATION****Ecotoxicity**

No data available

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****Sucrose:**Partition coefficient: n- : Pow: < 1  
octanol/water**Mobility in soil**

No data available

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Environmentally hazardous	: no

**IATA-DGR**

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

Not applicable

---

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

**Substances Subject to be Notified Names**

Not applicable

**Substances Subject to be Indicated Names**

Not applicable

**Skin and Eye Damage Substances (ISHL MO Art. 594-2)**

Not applicable

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

**Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

**Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

**Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

**Poisonous and Deleterious Substances Control Law**

Not applicable

**Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

**High Pressure Gas Safety Act**

Not applicable

**Explosive Control Law**

Not applicable

**Vessel Safety Law**

Not regulated as a dangerous good

**Aviation Law**

Not regulated as a dangerous good

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)  
Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

**16. OTHER INFORMATION****Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-

**Pembrolizumab Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
8.1	2025/04/14	49570-00028	Date of first issue: 2015/01/23

---

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN